These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The regulatory role of the United States Food and Drug Administration. Ortiz EM J Reprod Med; 1972 Apr; 8(4):205-6. PubMed ID: 5029971 [No Abstract] [Full Text] [Related]
25. Federal Food And Drug Administration. Revised New-Drug Regulations. Title 21--Food And Drugs. J Oral Ther Pharmacol; 1967 Sep; 4(2):148-64. PubMed ID: 6062044 [No Abstract] [Full Text] [Related]
26. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration. Kelsey FO Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617 [No Abstract] [Full Text] [Related]
28. DEA lists embutramide as schedule III controlled substance. J Am Vet Med Assoc; 2006 Nov; 229(9):1358. PubMed ID: 17139797 [No Abstract] [Full Text] [Related]
29. Relative efficacy. Stetler CJ J Miss State Med Assoc; 1972 Oct; 13(10):427-32. PubMed ID: 5070310 [No Abstract] [Full Text] [Related]
30. Instrument of impediment. The regulatory monograph in medical communications. Archer J J Kans Med Soc; 1972 Aug; 73(8):385-8. PubMed ID: 5068010 [No Abstract] [Full Text] [Related]
31. Current FDA policy on use of human-labeled drugs in animals. Teske RH J Am Vet Med Assoc; 1993 May; 202(10):1632-3;discussion 1634. PubMed ID: 8514570 [No Abstract] [Full Text] [Related]
32. New classification of drugs. J Fla Med Assoc; 1972 Jan; 59(1):37. PubMed ID: 5058956 [No Abstract] [Full Text] [Related]
34. Legal implications of preparing and dispensing approved drugs for unlabeled indications. Podell LB Am J Hosp Pharm; 1983 Jan; 40(1):111-3. PubMed ID: 6823981 [TBL] [Abstract][Full Text] [Related]
35. [Proposals for the legal control of the testing and introduction of drugs based on a comparison of drug laws in other countries]. Burow W; Lüllmann H Schriftenr Geb Off Gesundheitswes; 1971; 31():1-64. PubMed ID: 5153578 [No Abstract] [Full Text] [Related]
36. Editorial: The FDA reversed. Davis CE Va Med Mon (1918); 1974 Jan; 101(1):15-6. PubMed ID: 4809396 [No Abstract] [Full Text] [Related]
37. Hormonal and antimicrobial therapy in theriogenology practice: currently approved drugs in the USA and possible future directions. Modric T; Momcilovic D; Gwin WE; Peter AT Theriogenology; 2011 Aug; 76(3):393-408. PubMed ID: 21601267 [TBL] [Abstract][Full Text] [Related]
38. On the "costs" of the 1962 drug amendments. Smith MC; Visconti JA Inquiry; 1974 Mar; 11(1):61-4. PubMed ID: 4274295 [No Abstract] [Full Text] [Related]
39. Response to comments on the proposed model of a professional drug label. Martinez MN; Brown SA; Copeland DD; Haibel GK; Koritz GD; Riddell MG; Riviere JE; Rollins LD J Am Vet Med Assoc; 1996 Dec; 209(12):2068-70. PubMed ID: 8960188 [No Abstract] [Full Text] [Related]
40. FDA in hot water again over cost of proposed drug labeling rule. Demkovich LE Natl J (Wash); 1979 Sep; 11(38):1568-70. PubMed ID: 10243426 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]